These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 21371602

  • 1. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T.
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fragment-based ligand discovery.
    Fischer M, Hubbard RE.
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [Abstract] [Full Text] [Related]

  • 6. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine.
    Vulpetti A, Hommel U, Landrum G, Lewis R, Dalvit C.
    J Am Chem Soc; 2009 Sep 16; 131(36):12949-59. PubMed ID: 19702332
    [Abstract] [Full Text] [Related]

  • 7. Recent progress in fragment-based lead discovery.
    Schulz MN, Hubbard RE.
    Curr Opin Pharmacol; 2009 Oct 16; 9(5):615-21. PubMed ID: 19477685
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M, Ohno K, Niimi T.
    Drug Discov Today; 2009 Mar 16; 14(5-6):321-8. PubMed ID: 19028598
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM.
    Methods Enzymol; 2011 Mar 16; 493():169-218. PubMed ID: 21371592
    [Abstract] [Full Text] [Related]

  • 13. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M, Spadola L, Lundquist B, Hawtin P, Dahmén J, Groth-Clausen I, Nilsson E, Persdotter S, von Wachenfeldt K, Folmer RH, Edman K.
    J Med Chem; 2008 Apr 10; 51(7):2178-86. PubMed ID: 18341273
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R, Wang P, Wu J, Ruan K.
    Molecules; 2016 Jul 16; 21(7):. PubMed ID: 27438813
    [Abstract] [Full Text] [Related]

  • 19. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F, Caronni D, Colombo M, Dalvit C, Paolucci M, Regazzoni L, Visco C, Fogliatto G.
    Eur J Pharm Sci; 2015 Aug 30; 76():83-94. PubMed ID: 25952103
    [Abstract] [Full Text] [Related]

  • 20. NMR fragment screening: Advantages and applications.
    Schade M.
    IDrugs; 2006 Feb 30; 9(2):110-3. PubMed ID: 16523400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.